Scientists don't fully understand what causes Alzheimer's disease yet and success on the vaccines front has been limited, but Johnson & Johnson and Swiss biopharma AC Immune will nonetheless be partnering to develop a therapeutic vaccine for the disease.
J&J steps in with a $509M-plus deal to partner on a tau vaccine for Alzheimer's
After diving deep into the amyloid beta theory on Alzheimer's and coming up empty-handed--so far--Johnson & Johnson is partnering with Switzerland's AC Immune on an early-stage therapeutic vaccine that targets tau tangles as a prime suspect in triggering the memory-wasting ailment.
Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug
An Alzheimer's treatment from AC Immune and Genentech posted mixed results in a midstage study, missing its coprimary endpoints but performing well in patients with milder symptoms. That leaves Roche, Genentech's parent company, with a big decision to make on whether to take the plunge into Phase III.
AC Immune and Piramal Imaging link in Alzheimer's imaging agent development deal
AC Immune and Piramal Imaging are betting that an Alzheimer's imaging agent focused on tau proteins will be more valuable and successful in a market in which amyloid-β imaging agents designed to help diagnose the neurodegenerative disease have struggled to gain traction.
The Switzerland-based biotech has raised $22 million from German billionaire Dietmar Hopp and other backers to advance its Alzheimer's vaccine candidate, ACI-35, into clinical trials.
Billionaire backs new program for a pioneering Alzheimer's vaccine from AC Immune
German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer's programs.
10 Top Women in Biotech 2012
Each of these women has been inspired and advised by others before them, and several cited the ability and willingness to surround themselves with strong mentors and to pass on their knowledge to others. Paula Brown Stafford, president of clinical development at Quintiles, spends much of her time serving as an adviser to others. And as Andrea Pfeifer of AC Immune (a 2012 Fierce 15 company) put it, as a woman in a position of power in this industry, "you become a little bit of a model for young people." Read the full report >>
Defining 'fierce' in the modern age of drug and device development
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
FierceBiotech's 2012 Fierce 15 at BioPharm America
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
The Fierce 15: An appetite for risk is healthy in drug development
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >> Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>